Baron Funds made the following comment about 10x Genomics, Inc. (NASDAQ:TXG) in its Q3 2022 investor letter: "10x Genomics, Inc. (NASDAQ:TXG) sells products that offer life sciences researchers ...

Baron Discovery Fund highlighted stocks like 10x Genomics, Inc. (NASDAQ:TXG) in the Q3 2023 investor letter.Headquartered in Pleasanton, California, 10x Genomics, Inc. (NASDAQ:TXG) is a science ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where 10x Genomics, Inc. (NASDAQ:TXG) stands against the other genomics ...

The Brown Capital Management Small Company Fund highlighted stocks like 10x Genomics, Inc. (NASDAQ:TXG), in the first quarter 2024 investor letter. 10x Genomics, Inc. (NASDAQ:TXG) is a life ...

10x Genomics set terms for its planned initial public offering on Tuesday, saying in a regulatory filing that it plans to offer 9 million shares priced at $31 to $35 each. The company would raise ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

10x Genomics (TXG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Price Targets: Understanding forecasts, analysts offer estimates for 10x Genomics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

10x Genomics reported 18% YoY revenue growth in Q4, reaching $184M, with instruments revenue seeing a remarkable surge of 71%. Find out why TXG is poised for sustained growth.

Genomics startup Parse Biosciences lost its bid to dismiss a patent-infringement lawsuit brought by rival 10x Genomics and Stanford University on Thursday, when a Delaware federal court denied ...